biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 6.8

an Open Access Journal by MDPI

New Perspectives on Neuronal Cytoskeletal Dysregulation in Health and Disease

Guest Editors:

Dr. Arjun Singh
Molecular Pharmacology Program, Laboratory of Signal Transduction, Mortimer B. Zuckerman Research Center, 417 East 68th Street, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Dr. Rajvir Singh
Molecular Pharmacology Program, Laboratory of Signal Transduction, Mortimer B. Zuckerman Research Center, 417 East 68th Street, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Deadline for manuscript submissions:
closed (20 December 2023)

Message from the Guest Editors

Neurons have distinct and specialized morphological characteristics that allow them to receive, process, and transmit information. Because axons in humans can extend up to one meter in length, the presence of both the neuronal cytoskeleton and mitochondria is required to establish and maintain the polarity and physiological properties of these enormous structures. The neuronal cytoskeleton is made up of actin filaments, intermediate filaments, and microtubules, which help to transmit electrical and chemical signals between neurons and regulate the balance between motility and stability in neuronal structures.

Articles focused on understanding the pathophysiology of the neuronal cytoskeleton and Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and many other neurodegenerative diseases and/or their synergistic effects during CNS disorders are welcome in this Special Issue.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 6.8

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI